We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Assay Monitors Cardiomyopathy in Chagas Disease

By LabMedica International staff writers
Posted on 08 Mar 2011
A serum assay for a protein in the blood has been used to monitor damage to the heart in patients with chronic Chagas disease. More...


A highly sensitive assay for measuring the protein biomarker, cardiac troponin T (cTnT), has been used to assess heart injury in patients suffering from the tropical disease caused by the blood-borne protozoan parasite, Trypanosoma cruzi.

In an international study carried out at the Charité University Hospital, (Berlin, Germany), serum cTnT was measured in 26 healthy subjects and in 179 patients with chronic Chagas disease, of whom 86 were asymptomatic, 71 were suffering from cardiomyopathy with or without megacolon, and 22 were suffering from megacolon exclusively. Megacolon is an abnormal dilation of the colon is often accompanied by a paralysis of the peristaltic movements of the bowel.

For serum cTnT measurement, the conventional, fourth-generation assay and the highly sensitive assay provided by Roche Diagnostics GmbH (Mannheim, Germany), were performed using Roche's Elecsys-2010 chemistry analyzer. Serum cTnT was significantly higher in patients with cardiomyopathy with or without megacolon than in healthy subjects, asymptomatic subjects, and patients with megacolon, and the cTnT value was correlated with the severity of the cardiomyopathy. The lower limit of detection for the highly sensitive assay, was 3 ng/L, and was best at distinguishing patients with, and without, heart injury. C-reactive protein and interleukin 6 were found to parallel cTnT changes in both the different Chagas groups and the cardiomyopathy groups separated by disease severity.

The authors commented that the introduction of cardiac troponin immunoassays with improved sensitivity enables the mirroring of minor, but distinct, cardiac troponin elevations with diagnostic and prognostic effect in pathophysiological conditions of the heart, such as inflammation and cardiomyopathy. With the highly sensitive cTnT assay, a diagnostic tool is now available that supplies data usable in chronic Chagas disease for diagnosis, prognosis, and monitoring of cardiomyopathy. The cTnT measurement could, in their view, supplement electrocardiography, echocardiography, and radiological imaging in patients with chronic Chagas disease, and in special circumstances, be applied before these other diagnostic tools. The study was published in February 2011, in the Archives of Pathology and Laboratory Medicine.

Related Links:

Charité University Hospital
Roche Diagnostics



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.